XORTX Therapeutics to Vote on 5-for-1 Share Consolidation and Director Elections
XORTX Therapeutics filed its meeting materials on March 2, 2026 and mailed proxies for its Annual and Special Shareholders Meeting on March 24, 2026 where investors will vote on five director seats, auditor appointment, stock option plan approval and up to a 5-for-1 share consolidation. Proxy voting closes March 20, 2026 at 10:00 a.m. Calgary Time.
1. Filing and Distribution of Meeting Materials
XRTX Therapeutics filed its notice of meeting, management information circular and related documents with securities regulators and mailed them to shareholders on March 2, 2026. Shareholders can access the materials online, which include proxy forms and detailed voting instructions.
2. Meeting Agenda
Shareholders will vote on fixing the board size at five directors, electing directors, appointing the auditor and setting its remuneration, confirming the stock option plan and approving an amendment to consolidate up to five pre-consolidation common shares into one post-consolidation share.
3. Share Consolidation Details
The proposed share consolidation would combine up to five pre-consolidation shares into one post-consolidation share, as described in the circular, effectively reducing the total share count and potentially adjusting trading liquidity and per-share metrics.
4. Voting Procedures and Deadlines
Shareholders of record as of February 20, 2026 may vote online, by telephone or by proxy form. The proxy voting deadline is March 20, 2026 at 10:00 a.m. Calgary Time, and shareholders are encouraged to submit votes in advance.